Spots Global Cancer Trial Database for hepatoblastoma
Every month we try and update this database with for hepatoblastoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | NCT02867592 | Adrenal Cortica... Alveolar Soft P... Central Nervous... Childhood Clear... Clear Cell Sarc... Ewing Sarcoma Hepatoblastoma Hepatocellular ... Osteosarcoma Recurrent Adren... Recurrent Alveo... Recurrent Clear... Recurrent Ewing... Recurrent Hepat... Recurrent Hepat... Recurrent Kidne... Recurrent Malig... Recurrent Osteo... Recurrent Prima... Recurrent Renal... Recurrent Rhabd... Recurrent Soft ... Recurrent Thyro... Refractory Adre... Refractory Alve... Refractory Clea... Refractory Ewin... Refractory Hepa... Refractory Hepa... Refractory Mali... Refractory Oste... Refractory Prim... Refractory Prim... Refractory Rena... Refractory Rhab... Refractory Soft... Refractory Thyr... Refractory Wilm... Renal Cell Carc... Rhabdomyosarcom... Soft Tissue Sar... Solid Neoplasm Thyroid Gland M... Wilms Tumor | Cabozantinib Cabozantinib S-... Pharmacological... | 2 Years - 30 Years | National Cancer Institute (NCI) | |
| Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | NCT04337177 | Solid Tumors Neuroblastoma Rhabdomyosarcom... Ewing Sarcoma Hepatoblastoma Medulloblastoma | VAL-413 Temozolomide | 1 Year - 30 Years | Valent Technologies, LLC | |
| A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | NCT01125800 | Medulloblastoma Rhabdomyosarcom... Neuroblastoma Hepatoblastoma Glioma Astrocytoma | LDE225 | 12 Months - 18 Years | Novartis | |
| Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors | NCT00179816 | Ewing's Sarcoma Soft Tissue Sar... Hepatoblastoma Hodgkin's Disea... Germ Cell Tumor | High-Dose Chemo... | - 21 Years | Ann & Robert H Lurie Children's Hospital of Chicago | |
| Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors | NCT02390843 | Retinoblastoma Clear Cell Sarc... Renal Cell Carc... Rhabdoid Tumor Wilms Tumor Hepatoblastoma Neuroblastoma Germ Cell Tumor... Ewings Sarcoma Non-rhabdomyosa... Osteosarcoma Rhabdomyosarcom... | Simvastatin Cyclophosphamid... Topotecan Myeloid growth ... | 1 Year - 29 Years | Emory University | |
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | NCT03220035 | Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ependymoma Ewing Sarcoma Hepatoblastoma Langerhans Cell... Malignant Germ ... Malignant Gliom... Osteosarcoma Peripheral Prim... Recurrent Child... Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... Rhabdoid Tumor Rhabdomyosarcom... Soft Tissue Sar... Wilms Tumor | Laboratory Biom... Vemurafenib | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| A Compassionate Use Program to Provide Access to Sodium Thiosulfate | NCT04132882 | Cisplatin-Induc... | Sodium Thiosulf... | 1 Month - 18 Years | TRPHARM | |
| Undifferentiated Embryonal Sarcoma of the Liver: Evaluation of the Relapse Profile According to the Therapies Administered | NCT05640960 | Hepatic Sarcoma | 1 Year - 25 Years | University Hospital, Strasbourg, France | ||
| Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | NCT00003926 | Brain and Centr... Childhood Germ ... Chordoma Kidney Cancer Liver Cancer Neuroblastoma Ovarian Cancer Retinoblastoma Sarcoma | amifostine trih... busulfan filgrastim melphalan thiotepa peripheral bloo... | 1 Year - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery | NCT03533582 | Childhood Hepat... Childhood Malig... Fibrolamellar C... Hepatoblastoma Hepatocellular ... | Carboplatin Cisplatin Doxorubicin Etoposide Fluorouracil Gemcitabine Irinotecan Laboratory Biom... Oxaliplatin Patient Observa... Resection Sorafenib Vincristine Sul... | - 30 Years | Children's Oncology Group | |
| Deep Learning Magnetic Resonance Imaging Radiomics for Diagnostic Value of Hepatic Tumors in Infants | NCT05170282 | Hepatoblastoma Hepatic Hemangi... | Radiomic Algori... | 0 Months - 12 Months | West China Hospital | |
| Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | NCT00003926 | Brain and Centr... Childhood Germ ... Chordoma Kidney Cancer Liver Cancer Neuroblastoma Ovarian Cancer Retinoblastoma Sarcoma | amifostine trih... busulfan filgrastim melphalan thiotepa peripheral bloo... | 1 Year - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Combined Modality Therapy in Hepatoblastoma: South Egypt Cancer Institute Experience | NCT02557750 | Hepatoblastoma | - 18 Years | Assiut University | ||
| Molecular Basis of Pediatric Liver Cancer | NCT03959800 | Childhood Liver... Liver Malignant... Embryonal Sarco... Hepatoblastoma Hepatocellular ... Rhabdoid Tumor ... | 0 Years - 99 Years | University of Pittsburgh | ||
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | NCT03220035 | Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ependymoma Ewing Sarcoma Hepatoblastoma Langerhans Cell... Malignant Germ ... Malignant Gliom... Osteosarcoma Peripheral Prim... Recurrent Child... Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... Rhabdoid Tumor Rhabdomyosarcom... Soft Tissue Sar... Wilms Tumor | Laboratory Biom... Vemurafenib | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| GastroIntestinal Cancer in Children and Adolescents | NCT05693519 | Gastrointestina... Colorectal Canc... Gastric Cancer Hepatoblastoma Hepatocellular ... Burkitt Lymphom... Neuroendocrine ... | 0 Years - 24 Years | Leiden University Medical Center | ||
| B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | NCT04483778 | Pediatric Solid... Germ Cell Tumor Retinoblastoma Hepatoblastoma Wilms Tumor Rhabdoid Tumor Carcinoma Osteosarcoma Ewing Sarcoma Rhabdomyosarcom... Synovial Sarcom... Clear Cell Sarc... Malignant Perip... Desmoplastic Sm... Soft Tissue Sar... Neuroblastoma Melanoma | second generati... second generati... Pembrolizumab | 0 Years - 26 Years | Seattle Children's Hospital | |
| Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | NCT05302921 | Osteosarcoma Ewing Sarcoma Rhabdomyosarcom... Relapsed Pediat... Refractory Pedi... Melanoma Hepatoblastoma Hepatocellular ... Neuroblastoma Wilms Tumor | Cryoablation Th... Nivolumab Ipilimumab | 1 Year - 39 Years | Children's National Research Institute | |
| Nab-paclitaxel in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors | NCT03507491 | Cancer | Gemcitabine Nab-paclitaxel | 6 Months - 30 Years | Emory University | |
| Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors | NCT00179816 | Ewing's Sarcoma Soft Tissue Sar... Hepatoblastoma Hodgkin's Disea... Germ Cell Tumor | High-Dose Chemo... | - 21 Years | Ann & Robert H Lurie Children's Hospital of Chicago | |
| Combined Modality Therapy in Hepatoblastoma: South Egypt Cancer Institute Experience | NCT02557750 | Hepatoblastoma | - 18 Years | Assiut University | ||
| A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment | NCT04928677 | Primary Extra-c... Recurrent or Re... | Codrituzumab | 1 Year - 21 Years | Memorial Sloan Kettering Cancer Center | |
| Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy | NCT05322187 | Transitional Ce... Hepatoblastoma Liver Cancer Pediatric Solid... Pediatric Cance... | PD-1 inhibitor | 5 Years - 14 Years | RenJi Hospital | |
| Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors | NCT02390843 | Retinoblastoma Clear Cell Sarc... Renal Cell Carc... Rhabdoid Tumor Wilms Tumor Hepatoblastoma Neuroblastoma Germ Cell Tumor... Ewings Sarcoma Non-rhabdomyosa... Osteosarcoma Rhabdomyosarcom... | Simvastatin Cyclophosphamid... Topotecan Myeloid growth ... | 1 Year - 29 Years | Emory University | |
| A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy | NCT02085148 | Pediatric Oncol... | Regorafenib (BA... Vincristine (Ce... Irinotecan (Iri... | 6 Months - 18 Years | Bayer | |
| B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | NCT04897321 | Pediatric Solid... Osteosarcoma Rhabdomyosarcom... Neuroblastoma Ewing Sarcoma Wilms Tumor Adrenocortical ... Desmoplastic Sm... Germ Cell Cance... Rhabdoid Tumor Clear Cell Sarc... Hepatoblastoma Melanoma Carcinoma Malignant Perip... Soft Tissue Sar... | Fludarabine Cyclophosphamid... MESNA B7-H3 CAR T cel... | - 21 Years | St. Jude Children's Research Hospital | |
| Evaluation of Lung Metastases Based on Ultrashort Echo Time MRI | NCT05763173 | Hepatoblastoma Radiology | - 14 Years | RenJi Hospital | ||
| Paediatric Hepatic International Tumour Trial | NCT03017326 | Hepatoblastoma Carcinoma, Hepa... | Cisplatin Doxorubicin Carboplatin 5Fluorouracil Vincristine Etoposide Irinotecan Gemcitabine Oxaliplatin Sorafenib | - 30 Years | University of Birmingham | |
| Hepatoblastoma Biology Study and Tissue Bank | NCT00228683 | Hepatoblastoma | Biology Study a... | 6 Months - 21 Years | Emory University | |
| EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | NCT03618381 | Pediatric Solid... Germ Cell Tumor Retinoblastoma Hepatoblastoma Wilms Tumor Rhabdoid Tumor Carcinoma Osteosarcoma Ewing Sarcoma Rhabdomyosarcom... Synovial Sarcom... Clear Cell Sarc... Malignant Perip... Desmoplastic Sm... Soft Tissue Sar... Neuroblastoma | second generati... second generati... | 1 Year - 30 Years | Seattle Children's Hospital | |
| T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR) | NCT04093648 | Hepatocellular ... Hepatoblastoma | TEGAR T cells Cytoxan Fludarabine | 1 Year - | Baylor College of Medicine | |
| Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy | NCT05322187 | Transitional Ce... Hepatoblastoma Liver Cancer Pediatric Solid... Pediatric Cance... | PD-1 inhibitor | 5 Years - 14 Years | RenJi Hospital | |
| Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies | NCT04308330 | Ewing Sarcoma Rhabdomyosarcom... Wilms Tumor Neuroblastoma Hepatoblastoma Germ Cell Tumor | Vorinostat | 1 Year - 30 Years | New York Medical College | |
| Yttrium-90 (TARE-Y90) in Children, Adolescents, and Young Adults With Liver Tumors | NCT04315883 | Hepatoblastoma Hepatocellular ... Rhabdoid Tumor ... Undifferentiate... Pediatric Liver... Liver Tumors | Quality of Life... Transarterial R... | 0 Years - 21 Years | Nemours Children's Clinic |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
